Plus Therapeutics gets code for cancer test

Plus Therapeutics has secured a new dedicated billing code from the AMA for its CNSide® CSF Tumor Cell Enumeration Test. This development is a significant step towards broader U.S. commercial adoption and easier reimbursement from payers. The new code will streamline the process for clinicians to utilize the test and will enable national tracking of its utilization, ultimately supporting the company's growth and market penetration in the oncology diagnostics space.